Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD -0.03%15 Days Sales Outstanding is 57.03 as of Jun. 2026, which is 2% above its 10-year median of 56.15. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 946 Drug Manufacturers companies, Galderma Group AG ranks better than 65.12% on this metric.
The historical rank and industry rank for Galderma Group AG's Days Sales Outstanding or its related term are showing as below:
XSWX:GALD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.94 Med: 56.15 Max: 60.47
Current: 58.4
During the past 5 years, Galderma Group AG's highest Days Sales Outstanding was 60.47. The lowest was 55.94. And the median was 56.15.
XSWX:GALD's Days Sales Outstanding is ranked better than 65.12% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.885
vs XSWX:GALD: 58.40
Galderma Group AG's Days Sales Outstanding
declined
from Jun. 2025 (62.30) to Jun. 2026 (57.03).
Galderma Group AG (XSWX:GALD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Galderma Group AG Days Sales Outstanding Related Terms
Galderma Group AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Days Sales Outstanding falls into.
Galderma Group AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Days Sales Outstanding of 57.03 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Galderma Group AG and its competitors. This is near median its historical median of 56.15. Over the past decade, Galderma Group AG's Days Sales Outstanding has ranged from 55.94 to 60.47. According to the industry distribution chart, Galderma Group AG ranks #330 out of 946 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Galderma Group AG's Days Sales Outstanding too high?
Galderma Group AG's current Days Sales Outstanding of 57.03 is near median its 10-year median of 56.15. Over the past 10 years, this metric has ranged from a low of 55.94 to a high of 60.47. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Galderma Group AG's value of 57.03 is 20.7% below this industry median. Based on the distribution chart, Galderma Group AG ranks #330 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #330 out of 946 companies for Days Sales Outstanding. This puts Galderma Group AG in the upper half of its industry. The industry median Days Sales Outstanding is 71.89. Galderma Group AG's value of 57.03 is 20.7% below this benchmark. Historically, Galderma Group AG's own Days Sales Outstanding has ranged from 55.94 to 60.47 over the past decade. While the company's 10-year median is 56.15 vs. the industry median of 71.89, Galderma Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Days Sales Outstanding of 57.03 is 20.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Days Sales Outstanding is 57.03, which is near median its own 10-year median of 56.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Days Sales Outstanding of 57.03. The current Days Sales Outstanding is 57.03, which is near median its 10-year median of 56.15 and 20.7% below the Drug Manufacturers industry median of 71.89. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Days Sales Outstanding is 57.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
